BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29179875)

  • 41. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
    Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
    BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland.
    Leinonen MK; Anttila A; Malila N; Dillner J; Forslund O; Nieminen P
    Br J Cancer; 2013 Nov; 109(11):2941-50. PubMed ID: 24136148
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Enhanced molecular techniques for the diagnosis of human papillomavirus infections].
    Ursu RG; Onofriescu M; Nemescu D; Iancu LS
    Rev Med Chir Soc Med Nat Iasi; 2009; 113(4):1205-10. PubMed ID: 20191900
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention.
    Surriabre P; Torrico A; Vargas T; Ugarte F; Rodriguez P; Fontaine V
    BMC Infect Dis; 2019 Oct; 19(1):842. PubMed ID: 31615443
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison Study of BD Onclarity HPV With digene HC2 High-Risk HPV DNA Test and Roche Cobas 4800 HPV for Detecting High-Risk Human Papillomavirus in Japan.
    Nakamura M; Nakade K; Orisaka S; Iwadare J; Mizumoto Y; Fujiwara H
    Am J Clin Pathol; 2019 Feb; 151(3):263-269. PubMed ID: 30260388
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High genotyping concordance between the digene HPV Genotyping RH Test and the Reverse Line Blot genotyping assay on GP5+/6+-PCR products.
    Geraets DT; Heideman DA; de Koning MN; Snijders PJ; Meijer CJ; van Doorn LJ; Quint WG
    J Clin Virol; 2009 Nov; 46 Suppl 3():S16-20. PubMed ID: 20129069
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-throughput genotyping of high-risk HPV by the digene HPV Genotyping LQ Test using GP5+/6+-PCR and xMAP technology.
    Geraets DT; Heideman DA; de Koning MN; Snijders PJ; van Alewijk DC; Meijer CJ; van Doorn LJ; Quint WG
    J Clin Virol; 2009 Nov; 46 Suppl 3():S21-6. PubMed ID: 20129070
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative analysis of cervical cytology and human papillomavirus genotyping by three different methods in a routine diagnostic setting.
    Padalko E; Ali-Risasi C; Mesmaekers S; Ryckaert I; Van Renterghem L; Lambein K; Bamelis M; De Mey A; Sturtewagen Y; Vastenavond H; Broeck DV; Weyers S; Praet M
    Eur J Cancer Prev; 2015 Sep; 24(5):447-53. PubMed ID: 25370681
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of a Newly Developed HPV Genotyping Assay (Mojin HPV Kit) with Cobas 4800 HPV Test for Detection of High-Risk HPV in Specimens Collected in SurePath Solution.
    Yang WW; Wang ZG; Chen GF; Shi JF; Chen J; Ma QH; Zhou J; Mao XD; Liu C; Yao XM
    Clin Lab; 2018 Mar; 64(3):387-391. PubMed ID: 29739098
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CIN2+ detection of the HPV DNA Array genotyping assay in comparison with the Cobas 4800 HPV test and cytology.
    Pesic A; Krings A; Hempel M; Preyer R; Chatzistamatiou K; Agorastos T; Kaufmann AM
    Virol J; 2019 Jul; 16(1):92. PubMed ID: 31337408
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical performance of the CLART human papillomavirus 2 assay compared with the hybrid capture 2 test.
    Pista A; Verdasca N; Oliveira A
    J Med Virol; 2011 Feb; 83(2):272-6. PubMed ID: 21181922
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of Multiplex Polymerase Chain Reaction for Detection of High-Risk Human Papillomavirus Genotypes in Women Attending Routine Cervical Cancer Screening in Harare.
    Marembo T; Dube Mandishora R; Borok M
    Intervirology; 2019; 62(2):90-95. PubMed ID: 31412350
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cervista HR and HPV 16/18 assays vs hybrid capture 2 assay: outcome comparison in women with negative cervical cytology.
    Kurian EM; Caporelli ML; Baker S; Woda B; Cosar EF; Hutchinson L
    Am J Clin Pathol; 2011 Nov; 136(5):808-16. PubMed ID: 22031321
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with cobas 4800 HPV and Hybrid Capture 2 tests for detection of high-grade lesions of the uterine cervix.
    Lapierre SG; Sauthier P; Mayrand MH; Dufresne S; Petignat P; Provencher D; Drouin P; Gauthier P; Dupuis MJ; Michon B; Ouellet S; Hadjeres R; Ferenczy A; Franco EL; Coutlée F
    J Clin Microbiol; 2012 Apr; 50(4):1240-4. PubMed ID: 22301023
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Significance and possible causes of false-negative results of reflex human Papillomavirus infection testing.
    Eltoum IA; Chhieng DC; Crowe DR; Roberson J; Jin G; Broker TR
    Cancer; 2007 Jun; 111(3):154-9. PubMed ID: 17477380
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prior cervical cytology and high-risk HPV testing results for 311 patients with invasive cervical adenocarcinoma: a multicenter retrospective study from China's largest independent operator of pathology laboratories.
    Xie F; Zhang L; Zhao D; Wu X; Wei M; Zhang X; Wu X; Fang H; Xu X; Yang M; Qi D
    BMC Infect Dis; 2019 Nov; 19(1):962. PubMed ID: 31711435
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the SureX HPV genotyping test for the detection of high-risk HPV in cervical cancer screening.
    Wei B; Mei P; Huang S; Yu X; Zhi T; Wang G; Xu X; Xiao L; Dong X; Cui W
    Virol J; 2020 Nov; 17(1):171. PubMed ID: 33168022
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessing the time dependence of prognostic values of cytology and human papillomavirus testing in cervical cancer screening.
    Isidean SD; Wang Y; Mayrand MH; Ratnam S; Coutlée F; Franco EL; Abrahamowicz M;
    Int J Cancer; 2019 May; 144(10):2408-2418. PubMed ID: 30411802
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Searching for an ideal cervical cancer screening model to reduce false-negative errors in a country with high prevalence of cervical cancer.
    Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
    J Obstet Gynaecol; 2020 Feb; 40(2):240-246. PubMed ID: 31340702
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
    Tay SK; Lin LE; Goh RC
    Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.